natgillin/translations-raw huggingface dataset:
• If the seal is broken. 
• Ako je uništen zaštitni poklopac.
Dose linearity 
Linearnost doza
Additionally in Crohn's disease, clearance was affected by C-reactive protein, TNF antagonist failure status and race (Asian versus non-Asian). 
Nadalje, kod Crohnove su bolesti na klirens utjecali i C-reaktivni protein, neuspjeh liječenja antagonistima TNF-a i rasa (Azijci naspram ostalih).
No data are available on the secondary transmission of infection by live vaccines in patients receiving STELARA. 
Podaci o sekundarnoj transmisiji infekcije primjenom živih cjepiva u bolesnika koji se liječe STELAROM nisu poznati.
Choose two different sites for these injections (e.g. one injection in the right thigh and the other injection in the left thigh), and give the injections one right after the other. 
Za te injekcije odaberite dva različita mjesta primjene (npr. jednu injekciju u desno bedro, a drugu injekciju u lijevo bedro) i primijenite injekcije točno jednu za drugom.
Check the pre-filled syringe(s) to make sure 
Provjerite napunjenu štrcaljku (ili štrcaljke) kako biste bili sigurni
Caution should be exercised when considering the use of STELARA in patients with a chronic infection or a history of recurrent infection (see section 4.3). 
Mora se biti oprezan kod razmatranja primjene STELARE u bolesnika s kroničnom infekcijom ili rekurentnom infekcijom u anamnezi (vidjeti dio 4.3).
• Used syringes and needles should be placed in a puncture-resistant container, like a sharps container. 
• Upotrijebljene štrcaljke i igle moraju se odložiti u spremnik koji se ne može probušiti, poput spremnika za oštre predmete.
Psoriasis or Psoriatic Arthritis 
Psorijaza ili psorijatični artritis
The safety data described below reflect exposure in adults to ustekinumab in 14 phase 2 and phase 3 studies in 6,709 patients (4,135 with psoriasis and/or psoriatic arthritis, 1,749 with Crohn's disease and 825 patients with ulcerative colitis). 
Niže opisani podaci o sigurnosti primjene odražavaju izloženost odraslih bolesnika ustekinumabu u 14 ispitivanja faze II i III u 6709 bolesnika (4135 s psorijazom i/ili psorijatičnim artritisom, 1749 s Crohnovom bolesti i 825 bolesnika s ulceroznim kolitisom).
The median steady-state trough concentration ranged from 0.21 μg/mL to 0.26 μg/mL (45 mg) and from 0.47 μg/mL to 0.49 μg/mL (90 mg). 
Medijan stabilne najniže koncentracije kretao se od 0,21 μg/ml do 0,26 μg/ml (45 mg) te od 0,47 μg/ml do 0,49 μg/ml (90 mg).
• Pull the needle cover straight off and throw it away. 
• Povucite zaštitnu kapicu s igle tako da ju ravno povučete s igle i bacite ju.
• Take the pre-filled syringe(s) out of the refrigerator. 
• Uzmite napunjenu štrcaljku (ili štrcaljke) iz hladnjaka.
• the vial is not damaged and the seal is not broken 
• da bočica nije oštećena, a zaštitni poklopac nije slomljen
The proportion of patients with a PGA score of cleared (0) or minimal (1) at week 12 was 77.3%. 
Udio bolesnika kod kojih je u 12. tjednu zabilježen PGA skor čist (0) ili minimalan (1) iznosio je 77,3%.
The median CL/F in patients with weight > 100 kg was approximately 55% higher compared to patients with weight ≤ 100 kg. 
Medijan CL/F kod bolesnika težine > 100 kg bio je približno 55% viši u usporedbi s bolesnicima s težinom ≤ 100 kg.
Approximately 50% of the patients had failed at least 1 prior anti-TNF therapy (of which 48% were primary non-responders) and 17% had failed at least 1 anti-TNFα therapy and vedolizumab. 
Približno 50% bolesnika imalo je najmanje 1 neuspješnu prethodnu anti-TNFα terapiju (od kojih 48% nije ostvarilo primarni odgovor), a njih 17% bilo je neuspješno liječeno najmanje jednom anti-TNFα terapijom i vedolizumabom.
Corticosteroid-free clinical remission is defined as patients in clinical remission and not receiving corticosteroids at Week 44. 
Klinička remisija bez kortikosteroida definirana je kao klinička remisija u bolesnika koji ne prima kortikosteroide u 44.tjednu.
The median tmax values of ustekinumab following a single subcutaneous administration of either 45 mg or 90 mg in patients with psoriasis were comparable to those observed in healthy subjects. 
Medijan tmax vrijednosti ustekinumaba nakon jedne supkutane primjene 45 mg ili 90 mg kod bolesnika s psorijazom mogle su se usporediti s onima uočenim kod zdravih ispitanika.
Tell your doctor or get emergency medical help straight away if you notice any of the following signs. 
Recite svom liječniku ili odmah pozovite hitnu medicinsku pomoć ako primjetite bilo koji od sljedećih znakova.
The medicinal product should not be used if the solution is discoloured or cloudy, or if foreign particulate matter is present. 
Lijek se ne smije primijeniti ako je otopina promijenila boju ili je zamućena ili ako su prisutne strane čestice.
The formation of anti-ustekinumab antibodies is associated with both increased clearance and reduced efficacy of ustekinumab, except in patients with Crohn's disease or ulcerative colitis where no reduced efficacy was observed. 
Nastanak protutijela na ustekinumab povezan je s povećanim klirensom i smanjenom djelotvornošću ustekinumaba, osim u bolesnika s Crohnovom bolešću ili ulceroznim kolitisom, kod kojih nije opažena smanjena djelotvornost.
STELARA 130 mg is for intravenous use only. 
STELARA 130 mg je samo za intravensku primjenu.
53% of these patients were either non-responsive, intolerant, or had a contraindication to other systemic therapy. 
53% od tih bolesnika ili nije reagiralo, nije podnosilo ili je imalo kontraindikacije na drugu sustavnu terapiju.
• When the plunger is pushed as far as it will go, take out the needle and let go of the skin 
• Kada je klip pritisnut do kraja, izvucite iglu iz kože i pustite kožu.
EDTA disodium salt dihydrate L-histidine 
EDTA dinatrijeva sol dihidrat L-histidin
What Stelara is and what it is used for What you need to know before you use Stelara How to use Stelara 
Što je Stelara i za što se koristi Što morate znati prije nego počnete primjenjivati Stelaru Kako primjenjivati Stelaru
Ustekinumab is a fully human IgG1κ monoclonal antibody to interleukin (IL)-12/23 produced in a murine myeloma cell line using recombinant DNA technology. 
Ustekinumab je potpuno ljudsko IgG1κ monoklonsko protutijelo protiv interleukina (IL)-12/23 proizvedeno u mišjoj staničnoj liniji mijeloma primjenom tehnologije rekombinantne DNK.
• If you weigh less than 60 kg, the recommended dose is 0.75 mg of Stelara per kg body weight. 
• Ukoliko je Vaša tjelesna težina manja od 60 kg, preporučena doza je 0,75 mg Stelare po kilogramu tjelesne težine.
Some patients who received STELARA in clinical studies developed cutaneous and non-cutaneous malignancies (see section 4.8). 
U nekih bolesnika koji su primali STELARU u kliničkim ispitivanjima, razvile su se kožne i ne-kožne maligne bolesti (vidjeti dio 4.8).
• Inject all of the medication by pushing in the plunger until the plunger head is completely between the needle guard wings (see Figure 5) 
• Primjenite cijelu količinu lijeka gurajući klip, sve dok glava klipa ne bude potpuno između krilaca štitnika igle (pogledajte sliku 5).
Additionally on the basis of clinical trial data in patients with ulcerative colitis, a positive exposure-response relationship was established between trough concentrations, and clinical remission and mucosal healing. 
Nadalje, na temelju podataka iz kliničkih ispitivanja u bolesnika s ulceroznim kolitisom utvrđena je pozitivna veza između izloženosti i odgovora, tj. između najnižih koncentracija i kliničke remisije te cijeljenja sluznice.
It is unknown whether ustekinumab is excreted in human breast milk. 
Nije poznato izlučuje li se ustekinumab u majčino mlijeko u ljudi.
• Do not touch the needle or let the needle touch anything 
• Nemojte odložiti štrcaljku ili dopustiti da igla da bilo što dotakne.
Ustekinumab has been shown to improve signs and symptoms, and health related quality of life in paediatric patients 6 years and older with plaque psoriasis. 
Ustekinumab je pokazao poboljšanje znakova i simptoma, te kvalitete života povezane sa zdravljem kod pedijatrijskih bolesnika s plak psorijazom u dobi od 6 godina i starijih.
At 1 year (week 52), 89% of patients re-randomised to maintenance treatment were PASI 75 responders compared with 63% of patients re-randomised to placebo (treatment withdrawal) (p < 0.001). 
U 1. godini (52. tjedan), 89% bolesnika ponovno randomiziranih na održavanje liječenja, imalo je odgovor PASI 75, u usporedbi sa 63% bolesnika ponovno randomiziranih na placebo (prekid liječenja) (p < 0,001).
The median V/F in patients with weight > 100 kg was approximately 37% higher as compared to patients with weight ≤ 100 kg. 
Medijan V/F kod bolesnika težine > 100 kg bio je približno 37% viši u usporedbi s bolesnicima težine ≤ 100 kg.
STELARA, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1). 
STELARA, primijenjena samostalno ili u kombinaciji s MTX, indicirana je za liječenje aktivnog psorijatičnog artritisa u odraslih bolesnika kada odgovor na prethodne nebiološke antireumatske lijekove koji modificiraju tijek bolesti (engl. disease-modifying anti-rheumatic drug, DMARD) nije bio odgovarajući (vidjeti dio 5.1).
The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn's disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn's disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in patients with ulcerative colitis. 
Na farmakokinetiku ustekinumaba nije utjecala istodobna primjena MXT, NSAIL, 6-merkaptopurina, azatioprina i oralnih kortikosteroida kod bolesnika s psorijatičnim artritisom, Crohnovom bolesti ili ulceroznim kolitisom, kao ni prethodna izloženost anti-TNFα lijekovima kod bolesnika s psorijatičnim artritisom ili Crohnovom bolesti ili prethodna izloženost biološkim lijekovima (npr. anti-TNFα lijekovima i/ili vedolizumabu) kod bolesnika s ulceroznim kolitisom.
Ustekinumab demonstrated a statistically significant decrease in the rate of progression of structural damage compared to placebo, as measured by change from baseline to week 24 in the total modified vdH-S score (mean ± SD score was 0.97 ± 3.85 in the placebo group compared with 0.40 ± 2.11 and 0.39 ± 2.40 in the ustekinumab 45 mg (p < 0.05) and 90 mg (p < 0.001) groups, respectively). 
Ustekinumab je pokazao statistički značajan pad brzine progresije strukturnih oštećenja u usporedbi s placebom, mjereno promjenom u odnosu na početnu vrijednost do 24. tjedna u ukupnom modificiranom vdH-S bodu (srednja vrijednost ± SD bod bio je 0,97 ± 3,85 u placebo skupini u usporedbi s 0,40 ± 2,11 i 0,39 ± 2,40 u skupini s 45 mg (p < 0,05) odnosno 90 mg (p < 0,001) ustekinumaba.
Paediatric patients 6 years and older with plaque psoriasis The safety of ustekinumab has been studied in two phase 3 studies of paediatric patients with moderate to severe plaque psoriasis. 
Pedijatrijski bolesnici s plak psorijazom u dobi od 6 godina i stariji Sigurnost ustekinumaba ispitana je u dvama ispitivanjima faze 3 provedenima u pedijatrijskih bolesnika s umjerenom do teškom plak psorijazom.
Serious infections occurred at the rate of 0.03 per patient-year of follow-up in ustekinumab-treated patients (30 serious infections in 930 patient-years of follow-up) and 0.03 in placebo-treated patients (15 serious infections in 434 patient-years of follow-up) (see section 4.4). 
Ozbiljne infekcije javile su se u stopi od 0,03 po bolesnik-godini praćenja za bolesnike liječene ustekinumabom (30 ozbiljnih infekcija u 930 bolesnik-godina praćenja), te 0,03 kod bolesnika u placebo grupi (15 ozbiljnih infekcija u 434 bolesnik-godine praćenja) (vidjeti dio 4.4).
The beneficial effect of ustekinumab on clinical response, mucosal healing and clinical remission was observed in induction and in maintenance both in patients who failed conventional therapy but not a biologic therapy, as well as in those who had failed at least one prior TNFα antagonist therapy including in patients with a primary non-response to TNFα antagonist therapy. 
Koristan učinak ustekinumaba na klinički odgovor, cijeljenje sluznice i kliničku remisiju opažen je tijekom uvodnog liječenja i terapije održavanja i u bolesnika koji su bili neuspješno liječeni konvencionalnom, ali ne i biološkom terapijom i u bolesnika koji su imali najmanje jednu neuspješnu prethodnu terapiju antagonistima TNFα, uključujući bolesnike bez primarnog odgovora na liječenje antagonistima TNFα.
• Pick up the syringe and remove the needle cover 
• Uzmite štrcaljku i uklonite poklopac igle.
If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Stelara and for at least 15 weeks after the last Stelara treatment. 
Ako ste žena generativne dobi, savjetuje Vam se izbjegavanje trudnoće, a dok primjenjujete Stelaru te barem 15 tjedana nakon posljednje primjene Stelare, morate koristiti odgovarajuću kontracepciju.
The proportion of patients with a PGA score of cleared (0) or minimal (1) and the proportion achieving PASI 75 showed separation between the ustekinumab treated group and placebo at the first post-baseline visit at week 4, reaching a maximum by week 12. 
Udio bolesnika s PGA skor čist (0) ili minimalan (1) i udjelom postignutog PASI 75 pokazao je odvajanje skupina liječenih ustekinumabom i placebom prilikom prve posjete nakon početka liječenja u 4. tjednu, postižući maksimum do 12. tjedna.
The CL/F of ustekinumab was not impacted by gender. 
Spol nije utjecao na CL/F ustekinumaba.
61% of these patients were either non-responsive, intolerant, or had a contraindication to other systemic therapy. 
61% od tih bolesnika ili nije reagiralo, nije podnosilo ili je imalo kontraindikacije na drugu sustavnu terapiju.
Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. 
Ustekinumab je potpuno ljudsko IgGlκ monoklonsko protutijelo koje se specifično veže na zajedničku p40 proteinsku podjedinicu ljudskog citokina interleukina (IL)-12 i IL-23.
Tell your doctor straight away if you notice any of these signs of infection. 
Odmah recite svom liječniku ako primjetite bilo koji od ovih znakova infekcije.
• If there are air bubbles, tap the side gently until the air bubbles go to the top of the syringe (see 
• Ako ima mjehurića zraka, lagano lupkajte postrance dok mjehurići zraka ne odu do vrha štrcaljke (pogledajte Sliku 5).
Patients previously treated with anti-TNFα agents who received ustekinumab achieved a greater response at week 24 than patients receiving placebo (ACR 20 response at week 24 for 45 mg and 90 mg was 37% and 34%, respectively, compared with placebo 15%; p < 0.05), and responses were maintained through week 52. 
Bolesnici prethodno liječeni anti-TNFα lijekovima koji su primili ustekinumab dostigli su bolji odgovor u odnosu na placebo skupinu u 24. tjednu (ACR 20 odgovor u 24. tjednu za 45 mg odnosno 90 mg bio je 37% odnosno 34%, u usporedbi s placebom 15%; p < 0,05), a odgovori su se održali kroz 52 tjedna.
• Tooth infections 
• infekcije zuba
Median systemic clearance (CL) following a single intravenous administration to patients with psoriasis ranged from 1.99 to 2.34 mL/day/kg. 
Medijan sustavnog klirensa (CL) nakon jedne intravenske primjene kod bolesnika s psorijazom kretao se od 1,99 do 2,34 ml/dan/kg.
The clinical development program consisted of two 8-week intravenous induction studies (UNITI-1 and UNITI-2) followed by a 44 week subcutaneous randomized withdrawal maintenance study (IM-UNITI) representing 52 weeks of therapy. 
Klinički razvojni program sastojao se od dva ispitivanja intravenske primjene uvodnog liječenja (UNITI-1 i UNITI-2) u trajanju od 8 tjedana, nakon čega je uslijedilo randomizirano ispitivanje supkutane primjene terapije održavanja u trajanju od 44 tjedna (IM-UNITI) što je predstavljalo 52 tjedna terapije.
• The first dose of Stelara for treatment of Crohn's disease or ulcerative colitis is given by a doctor as a drip in the vein of an arm (intravenous infusion). 
Prvu dozu Stelare za liječenje Crohnove bolesti ili ulceroznog kolitisa daje liječnik u obliku infuzije kap po kap (drip) u venu ruke (infuzija u venu).
Table 1 Initial intravenous dosing of STELARA Body weight of patient at the time of dosing 
Tablica 1 Inicijalno intravensko doziranje STELARE Tjelesna težina bolesnika u vrijeme doziranja
• Empty vials, antiseptic wipes, and other supplies can be disposed of in your garbage. 
• Prazne bočice, antiseptičke maramice te drugi pribor možete odložiti u kućni otpad.
In patients with psoriasis, steady-state serum concentrations of ustekinumab were achieved by week 28 after initial subcutaneous doses at Weeks 0 and 4 followed by doses every 12 weeks. 
U bolesnika s psorijazom, stabilne serumske koncentracije ustekinumaba ostvarene su do tjedna 28 nakon početnih supkutanih doza u tjednima 0 i 4, nakon čega su slijedile doze svakih 12 tjedana.
The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis clinical studies with ustekinumab were nasopharyngitis and headache. 
Najčešće prijavljene nuspojave (> 5%) u kontroliranim razdobljima kliničkih ispitivanja psorijaze, psorijatičnog artritisa, Crohnove bolesti i ulceroznog kolitisa kod odraslih bolesnika s ustekinumabom bile su nazofaringitis i glavobolja.
• Common signs of an allergic reaction include skin rash and hives (these may affect up to 1 in 100 people). 
• Česti znakovi alergijske reakcije uključuju kožni osip i koprivnjaču (mogu se pojaviti u 1 od 100 osoba).
During the 12-week active-controlled portion of the study, patients were randomised to receive etanercept (50 mg twice a week), ustekinumab 45 mg at Weeks 0 and 4, or ustekinumab 90 mg at Weeks 0 and 4. 
Tijekom 12 tjednog aktivno kontroliranog dijela ispitivanja, bolesnici su bili randomizirani u skupine liječene etanerceptom (50 mg dva puta tjedno), ustekinumabom 45 mg u tjednima 0 i 4 ili ustekinumabom 90 mg u tjednima 0 i 4.
In Crohn's disease, dose adjustment from 90 mg every 12 weeks to 90 mg every 8 weeks was associated with an increase in trough serum ustekinumab concentrations and an accompanying increase in efficacy. 
Kod Crohnove je bolesti prilagodba doziranja s 90 mg svakih 12 tjedana na 90 mg svakih 8 tjedana bila povezana s povišenjem najnižih serumskih koncentracija ustekinumaba i popratnim povećanjem djelotvornosti.
In PsA Study 2 significant improvement in enthesitis score and numerical improvement (not statistically significant) in dactylitis score was observed in the ustekinumab 90 mg group compared with placebo at week 24. 
U PsA ispitivanju 2, značajno poboljšanje bodova za entezitis i poboljšanje brojčane vrijednosti (nije bilo statistički značajno) bodova za daktilitis primijećeno je u skupini koja je primala ustekinumab od 90 mg u usporedbi s placebom u 24. tjednu.
At week 8, patients receiving ustekinumab showed statistically significantly greater and clinically meaningful improvements on IBDQ total score and SF-36 Mental Component Summary Score in both UNITI-1 and UNITI-2, and SF-36 Physical Component Summary Score in UNITI-2, when compared to placebo. 
U 8. tjednu, bolesnici koji su primali ustekinumab pokazali su statistički značajno veća i klinički značajna poboljšanja ukupnog IBDQ skora i SF-36 zbirnog skora mentalne komponenete i u UNITI-1 i UNITI-2, i SF-36 zbirnog skora fizičke komponenete u UNITI-2, u usporedbi s placebom.
Ustekinumab 2 doses (week 0 and week 4) 45 mg 
2 doze (Tjedan 0 i Tjedan 4) 45 mg
If you forget or miss the appointment for receiving the dose, contact your doctor to reschedule your appointment. 
Ako zaboravite ili propustite doći na zakazanu primjenu doze lijeka, kontaktirajte svog liječnika i ponovno dogovorite posjetu.
The systemic exposure of ustekinumab (Cmax and AUC) increased in an approximately dose-proportional manner after a single intravenous administration at doses ranging from 0.09 mg/kg to 4.5 mg/kg. 
Sustavna izloženost ustekinumabu (Cmax i AUC) povećala se na način približno proporcionalan dozi nakon jedne intravenske primjene u dozama koje se kreću od 0,09 mg/kg do 4,5 mg/kg
Shedding of skin - increase in redness and shedding of skin over a larger area of the body may be symptoms of erythrodermic psoriasis or exfoliative dermatitis, which are serious skin conditions. 
Ljuštenje kože - pojačano crvenilo i ljuštenje kože na većoj površini tijela mogu biti simptomi ozbiljnih poremećaja kože, eritrodermne psorijaze ili eksfolijativnog dermatitisa.
Live vaccines should not be given concurrently with STELARA (see section 4.4). 
Živa cjepiva ne smiju se koristiti istovremeno sa STELAROM (vidjeti dio 4.4).
Histologic & Histo-Endoscopic Mucosal Healing 
Histološko i histo-endoskopsko cijeljenje sluznice
Do not use if visibly opaque particles, discoloration or foreign particles are observed. 
Nemojte koristiti ako uočite neprozirne čestice, promjenu boje ili strane čestice.
Crohn's Disease and Ulcerative Colitis 
Crohnova bolest i ulcerozni kolitis
All patients were followed for up to 76 weeks following first administration of study treatment. 
Svi bolesnici praćeni su do 76 tjedana nakon prve primjene lijeka u ispitivanju.
In patients with Crohn's disease and ulcerative colitis, based on observed data and population PK analyses, randomized subjects who lost response to treatment had lower serum ustekinumab concentrations over time compared with subjects who did not lose response. 
Prema opaženim podacima i populacijskim farmakokinetičkim analizama, među bolesnicima s Crohnovom bolesti i ulceroznim kolitisom randomizirani ispitanici koji su izgubili odgovor na liječenje imali su niže koncentracije ustekinumaba u serumu tijekom vremena u usporedbi s ispitanicima koji nisu izgubili odgovor.
Make sure you tell your doctor about any illness you have before treatment. 
Svakako obavijestite liječnika o svim bolestima koje imate prije primjene lijeka.
Serum concentration-time profiles of ustekinumab were generally predictable after single or multiple subcutaneous dose administrations. 
Jednokratna doza u odnosu na višekratno doziranje Profili vremena serumske koncentracije ustekinumaba općenito su bili predvidljivi nakon jednokratne ili višekratne supkutane primjene.
Crohn's disease or Ulcerative Colitis 
Crohnova bolest ili ulcerozni kolitis
Calculate the dose and the number of STELARA vials needed based on patient weight (see section 4.2, Table 1). 
Izračunajte dozu i broj bočica STELARE koje trebate na temelju tjelesne težine bolesnika (vidjeti dio 4.2, Tablicu 1).
The first subcutaneous administration of 90 mg STELARA should take place at week 8 after the intravenous dose. 
Prva potkožna primjena 90 mg STELARE treba biti u 8. tjednu nakon intravenske doze.
Thus, ustekinumab is not likely to contribute to complement- or antibody-mediated cytotoxicity of cells with IL-12 and/or IL-23 receptors. 
Tako ustekinumab vjerojatno neće doprinijeti komplementarnoj ili protutijelima posredovanoj citotoksičnosti stanice koja nosi receptore IL-12 i/ili IL-23.
Table 7 Summary of primary and secondary endpoints at week 12 and week 52 Paediatric psoriasis study (CADMUS) (Age 12-17) Week 12 
Tablica 7: Sažetak primarnih i sekundarnih ishoda u 12. i 52. tjednu Ispitivanje pedijatrijske psorijaze (CADMUS) (dob od 12 do 17 godina) 12. tjedan
Calculate the dose and the number of STELARA vials needed based on patient weight (see section 3, Table 1). 
Izračunajte dozu i broj bočica STELARE koje trebate na temelju tjelesne težine bolesnika (vidjeti dio 3, tablicu 1).
The safety and efficacy of STELARA in children with psoriasis less than 6 years of age or in children with psoriatic arthritis less than 18 years of age have not yet been established. 
Pedijatrijska populacija Sigurnost i djelotvornost primjene STELARE u djece s psorijazom mlađe od 6 godina ili u djece s psorijatičnim artritisom mlađe od 18 godina još nisu ustanovljene.